Adaptive Biotechnologies Corporation — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing also reports unaudited fourth-quarter results. Adaptive is a commercial-stage biotechnology company developing immune-receptor sequencing, clinical diagnostics and cellular therapy programs. Its commercial offerings include immunoSEQ research services and the clonoSEQ minimal residual disease (MRD) test.
Financial performance and position
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $85.1 million | $55.7 million |
| Sequencing revenue | $43.5 million | $33.0 million |
| Development revenue | $41.6 million | $22.7 million |
| Cost of revenue | $22.3 million | $19.7 million |
| Gross margin, calculated | 73.8% | 64.7% |
| Operating expenses | $163.5 million | $105.4 million |
| Operating loss | $(78.4) million | $(49.8) million |
| Net loss | $(68.6) million | $(46.4) million |
| Adjusted EBITDA | $(57.5) million | $(32.6) million |
| Cash, cash equivalents and marketable securities | $682.3 million | $165.0 million |
Revenue increased 53% year over year. Sequencing revenue rose 32%, including a 48% increase in clinical tests delivered to 10,168; development revenue rose 83%, primarily reflecting the Genentech collaboration. Research and development expense increased 81% to $70.7 million, while sales and marketing expense rose 57% to $38.5 million. Operating loss widened as spending grew faster than revenue. The filing reports no income tax expense; deferred tax assets were fully offset by a valuation allowance.
Fourth quarter: Revenue was $24.2 million, versus $17.2 million in Q4 2018. Net loss was $20.6 million, versus $13.3 million. The filing does not provide a separate Q4 cash-flow statement.
Cash flow and liquidity: FY2019 operating cash flow was positive $205.4 million, compared with cash used of $32.3 million in 2018. The 2019 inflow was driven chiefly by a $266.9 million increase in deferred revenue, including Genentech’s $300 million upfront payment—not by positive net income. Investing activities used $481.7 million, primarily reflecting purchases of marketable securities; financing activities provided $319.9 million, largely from the IPO. Management said cash, investments and anticipated operating cash flows were expected to fund operations for at least 12 months.
At year-end, cash and cash equivalents were $96.6 million, and marketable securities were $585.7 million. Working capital was $534.4 million. Total liabilities were $341.3 million, including $280.3 million of deferred revenue and a $36.6 million lease financing obligation. No conventional borrowing balance is identified in the supplied filing text. Contractual operating lease and purchase commitments totaled $154.1 million.
Material changes and notable items
- Genentech paid a $300 million upfront fee in February 2019. Adaptive recognized $35.1 million of related revenue during the year and had $264.9 million of Genentech deferred revenue at year-end; the company estimated recognition over approximately seven to eight years. Further development, regulatory and commercial milestones of approximately $1.8 billion and tiered royalties are contingent, not assured.
- Adaptive completed its IPO in July 2019, issuing 17.25 million shares at $20 per share and receiving approximately $315.9 million in net proceeds. Convertible preferred stock converted to common stock at closing.
- Cash and investments increased substantially, alongside higher operating losses and materially higher R&D, commercial and administrative spending.
- Revenue concentration merits attention: the filing’s business discussion says Genentech represented approximately 41.3% of 2019 revenue, while the financial-statement note reports 42.1%. Investors should verify the correct percentage and its basis.
Outlook, commentary and risks
Management expects to continue investing in research, product validation, commercial adoption and laboratory capacity; it anticipates ongoing losses and does not provide quantified revenue or earnings guidance in the supplied text. Stated development objectives included a Genentech IND submission for the first shared cellular therapy by the end of 2020, and an immunoSEQ Dx submission for one indication by year-end 2020. These are forward-looking milestones, not guarantees. The company reported proof of concept for acute Lyme disease in retrospective cohorts; the test was still in development and required further validation and regulatory engagement.
- clonoSEQ had FDA authorization for MRD testing in bone marrow samples for multiple myeloma and acute lymphoblastic leukemia. Adaptive reported Medicare and private-payor coverage representing more than 175 million covered lives, but reimbursement levels, utilization and coverage expansion remain uncertain.
- Key execution risks include clinical and analytical validation, regulatory clearance, reimbursement, commercial adoption, and the ability to scale laboratory operations. The Genentech collaboration also gives Genentech control of clinical, regulatory and commercialization efforts and may be terminated by Genentech for convenience.
- Other material risks include dependence on Illumina sequencing equipment and reagents; evolving FDA oversight of laboratory-developed tests; competition; data privacy and cybersecurity; intellectual-property disputes; and the possibility that research or product candidates fail.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor issued an unqualified opinion on the financial statements but did not provide an internal-control attestation.
Most important facts for investors to verify
- Reconcile the disclosed Genentech revenue-concentration figures of 41.3% and 42.1%, and confirm the full revenue-recognition and deferred-revenue assumptions for the upfront payment.
- Track operating cash burn excluding the large Genentech advance, and assess whether the stated liquidity runway remains adequate as investment and expansion spending continues.
- Check progress and actual regulatory outcomes for the planned Genentech IND, immunoSEQ Dx submission, and clonoSEQ label or blood-sample expansions; confirm whether each target was met.
- Validate clonoSEQ test growth, repeat-use trends, collections and reimbursement rates—not just covered lives—and monitor dependence on collaborator and milestone revenue.
- Review the scale and terms of lease commitments, the $36.6 million lease financing obligation, potential equity dilution, and ongoing losses.